甲银屑病的生物制剂治疗研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.10.003

摘要/Abstract

摘要：

由于生物制剂在银屑病治疗中普遍应用，甲银屑病（nail psoriasis，NP）的治疗效果也有了显著提升。不同生物制剂作用靶点不同，疗效亦不同。近年来，生物制剂治疗NP的疗效观察逐渐增多，本文就生物制剂在NP中的应用效果进行综述，以期为临床治疗提供参考。

关键词:

甲银屑病, 生物制剂, 治疗, 进展

Abstract:

The use of biological agents in treating psoriasis has led to a significant enhancement in the effectiveness of addressing nail psoriasis. Different biological agents have different targets and different efficacies. The application and efficacy comparison of biological agents in nail psoriasis has been increasingly studied over the past few years, and this paper reviews them to provide clinical insight.

Key words:

Nail psoriasis, Biologics, Treatment, Progress

王慧王静马蕾高昱.

甲银屑病的生物制剂治疗研究进展 [J]. 国际医药卫生导报, 2024, 30(10): 1594-1597.

Wang Hui, Wang Jing, Ma Lei, Gao Yu.

Advances in the study of biologic therapy for nail psoriasis [J]. International Medicine and Health Guidance News, 2024, 30(10): 1594-1597.

参考文献

[1] Elewski BE, Blauvelt A, Gallo G, et al. Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis[J]. Dermatol Ther (Heidelb), 2022, 12(4):911-920. DOI: 10.1007/s13555-022-00704-2.
[2] Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis[J]. Reumatologia, 2017, 55(3):131-135. DOI: 10.5114/reum.2017.68912.
[3] 周舟,郝飞.甲银屑病的局部治疗研究进展[J].临床皮肤科杂志,2018,47(2):132-133. DOI:10.16761/j.cnki.1000- 4963.2018.02.024.
[4] Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus[J]. J Am Acad Dermatol, 2019, 81(1):228-240. DOI: 10.1016/j.jaad.2019.01.072.
[5] Yew YW, Phuan CZY, Zhao X, et al. Novel transdermal device for delivery of triamcinolone for nail psoriasis treatment[J]. Ann Acad Med Singap, 2022, 51(1):16-23. DOI: 10.47102/annals-acadmedsg.2021380.
[6] Stern DK, Creasey AA, Quijije J, et al. UV-A and UV-B penetration of normal human cadaveric fingernail plate[J]. Arch Dermatol, 2011, 147(4):439-441. DOI: 10.1001/archdermatol.2010.375.
[7] Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis[J]. J Eur Acad Dermatol Venereol, 2009, 23(8):896-904. DOI: 10.1111/j.1468-3083.2009.03211.x.
[8] Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year[J]. J Am Acad Dermatol, 2008, 58(2):224-231. DOI: 10.1016/j.jaad.2007.07.042.
[9] Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial[J]. J Eur Acad Dermatol Venereol, 2019, 33(11):2168-2178. DOI: 10.1111/jdv.15793.
[10] Kokolakis G, Bachmann F, Wolk K, et al. Efficacy of adalimumab for nail psoriasis during 24 months of continuous therapy[J]. Acta Derm Venereol, 2020, 100(14):adv00214. DOI: 10.2340/00015555-3545.
[11] Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) [J]. Ann Rheum Dis, 2014, 73(1):48-55. DOI: 10.1136/annrheumdis-2013-203696.
[12] Mease P, Elaine Husni M, Chakravarty SD, et al. Evaluation of improvement in skin and nail psoriasis in bio-naïve patients with active psoriatic arthritis treated with golimumab: results through week 52 of the GO-VIBRANT study[J]. ACR Open Rheumatol, 2020, 2(11):640-647. DOI: 10.1002/acr2.11180.
[13] Rigopoulos D, Gregoriou S, Makris M, et al. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study[J]. Dermatology, 2011, 223(4):325-329. DOI: 10.1159/000334482.
[14] Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1[J]. Br J Dermatol, 2014, 170(2):398-407. DOI: 10.1111/bjd.12632.
[15] Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab[J]. J Eur Acad Dermatol Venereol, 2022, 36(9):1568-1577. DOI: 10.1111/jdv.18218.
[16] Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis[J]. J Clin Med, 2022, 11(9):2631. DOI: 10.3390/jcm11092631.
[17] Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period[J]. Arch Dermatol Res, 2022, 314(6):619-623. DOI: 10.1007/s00403-021-02200-7.
[18] Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study[J]. Dermatol Ther, 2022, 35(7):e15524. DOI: 10.1111/dth.15524.
[19] Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study[J]. Br J Dermatol, 2021, 184(3):425-436. DOI: 10.1111/bjd.19262.
[20] Husein-ElAhmed H, Husein-ElAhmed S. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis[J]. Clin Exp Dermatol, 2023, 48(8):895-902. DOI: 10.1093/ced/llad136.
[21] Egeberg A, Kristensen LE, Vender R, et al. Sustained resolution of nail psoriasis through 5 years with ixekizumab: a post-hoc analysis from UNCOVER-3[J]. Acta Derm Venereol, 2022, 102:adv00787. DOI: 10.2340/actadv.v102.2269.
[22] Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis[J]. J Dermatolog Treat, 2022, 33(3):1652-1660. DOI: 10.1080/09546634.2021.1892024.
[23] Paller AS, Seyger MMB, Magariños GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial[J]. JAMA Dermatol, 2022, 158(5):533-541. DOI: 10.1001/jamadermatol.2022.0655.
[24] Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials[J]. J Dermatolog Treat, 2022, 33(1):261-265. DOI: 10.1080/09546634.2020.1749546.
[25] Saraceno R, Pietroleonardo L, Mazzotta A, et al. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis[J]. Expert Opin Biol Ther, 2013, 13(4):469-473. DOI: 10.1517/14712598.2013.736960.
[26] Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study[J]. J Dermatolog Treat, 2022, 33(6):2813-2820. DOI: 10.1080/09546634.2022. 2081655.
[27] Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial[J]. Br J Dermatol, 2021, 184(6):1047-1058. DOI: 10.1111/bjd.19509.
[28] Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial[J]. Ann Rheum Dis, 2020, 79(1):123-131. DOI: 10.1136/annrheumdis-2019- 215386.
[29] van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3[J]. J Eur Acad Dermatol Venereol, 2017, 31(3):477-482. DOI: 10.1111/jdv.14033.
[30] Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials[J]. JAMA Dermatol, 2018, 154(6):676-683. DOI: 10.1001/jamadermatol.2018.0793.
[31] Jo SJ, Huang YH, Tsai TF, et al. Efficacy of guselkumab in difficult-to-treat psoriasis regions: data from VOYAGE 1 and VOYAGE 2 Asian subpopulations[J]. J Dermatol, 2023, 50(9):1180-1189. DOI: 10.1111/1346-8138.16865.